Most autoimmune targeting therapies aim to tune-down, regulate or re-polarize the existing T cell response. Conversely, immuno-oncology strategies attempt to mobilize a novel anti-tumor response or take the brakes off the existing anti-tumor T cell response.
As T cell therapies within both areas become more sophisticated in targeting and refining T cell function or polarization, we can deepen our knowledge by examining the mode of action and strategies of T cell directed therapies in a disease agnostic manner.
Join us for a virtual exploration of these opposing objectives, where experts discuss strategies to enhance or limit T cell function to advance innovation within autoimmune and immuno-oncology fields for therapies that target specific T cell function.
3 Takeaways From This Virtual Symposium
- Examine the mode of action & strategies of T cell directed therapies in a disease-agnostic setting
- Discover strategies to enhance or limit T cell function to advance innovation within autoimmune & immuno-oncology fields
- Gain an insight into the approaches used to assess therapeutics through modulating T cell functions
Register for this virtual event to join the discussion...
Tuesday, November 24, 2020 (EST)
|9:00 – 9:15 AM
Welcome and Opening Remarks
|9:15 – 9:40 AM
Checkpoint Inhibitors & Agonists – How to Translate it to Autoimmune Research
Howard Kaufman, MD, IMMUNEERING CORP
|9:40 – 10:05 AM
Cellular Therapy – IO & Autoimmune (AI)/Inflammation
Duncan Howie PhD, Enara Bio
|10:05 – 10:15 AM
|10:15 – 10:40 AM
The Role of the Microbiome in AI/IO
Jemila Kester, PhD, Kaleido Biosciences
|10:40 – 11:05 AM
How to Select The Most Appropriate Models for Testing
Louise Brackenbury, PhD Charles River and Julia Schüler, PhD, Charles River
|11:05 – 11:25 AM
*Agenda is subject to change.
Jemila Kester, PhD
Scientist, Immuno-oncology Group, Kaleido Biosciences
Dr. Kester has studied host immunologic responses in the fly, mouse, and human. She holds a PhD from Harvard School of Public Health and was a postdoctoral associate at MIT, where she contributed to the development of a human gut-immune-microbiome chip capable of supporting both aerobic and anaerobic growth simultaneously, furthering our understanding of human immune and microbiome interdependence. Dr. Kester has won several awards and fellowships, from the NIH, NSF and HHMI grants. At Kaleido Biosciences, she uses in vivo, in vitro, and ex vivo models to understand host-microbe interactions in cancer immunology.
Duncan Howie, PhD
Associate Director, Immunology, Enara Bio
Dr. Howie is an experienced immuno-oncology focused immunologist with specialized skill in cellular immunology, immunometabolism, therapeutics, and molecular biology. He obtained his PhD in Immunology from University of London.
Howard Kaufman, MD
Head, Research and Development, IMMUNEERING CORP
As Chief Medical Officer, Dr. Kaufman leads Immuneering Corp R&D with considerable expertise in cancer immunotherapy and drug development. With a background in both academic medicine and biotechnology, he has rich experience in cancer research, biotechnology, healthcare and its management and the life sciences industry.
Louise Brackenbury, PhD
Principal Scientist, Cell Biology, Discovery Services, Charles River
Louise Brackenbury received her PhD in viral immunology from UCL, prior to two post-doctoral fellowships at Imperial College and Bristol University. Louise joined KWS BioTest in 2012, then Charles River in 2018 following the acquisition of KWS BioTest where she leads the Cell biology team as a Principal Scientist. With expertise in immunology and cell biology, she has used this to develop a wide range of autoimmunity and IO assays for in vitro testing and has overseen drug discovery programmes for multiple clients, primarily in pre-clinical testing.
Rhiannon Jenkinson, PhD
Director of Science, Discovery Services, Charles River
Rhiannon Jenkinson is Director of Science at Charles River Laboratories Portishead. She experience working at Charles River leading and designing projects for clients in the fields of autoimmunity, inflammation and oncology. This builds on her academic experience within the immunology and oncology fields.
Her previous positions have included a Wellcome Trust Career Re-entry Fellowship, focusing on the role of T cells in epithelial repair in the gut and skin, a six year fellowship at the NIH, NCI where her research focused on T cell development and tumour immunology, a post-doctoral position at the University of Bristol, studying T cell responses to tumours and PhD studying a gene which drives breast cancer metastasis.
Julia Schüler, DVM, PhD
Research Director, Charles River
Julia Schüler, PhD, studied veterinary medicine at the Freie Unversität Berlin (Germany) and at the Tierspital Zürich (Switzerland), where she received her DVM. She then joined the lab of Prof. Dr. Heiner Fiebig, founder of Oncotest GmbH, where she worked on orthotopic implantation of solid cancer PDX in immunocompromized mice.
After receiving her PhD from the University of Berlin, Dr. Schüler worked in the field of innate immunology at the Max-Planck Institute for Immunobiology, Freiburg, in the group of Dr. Marinus Lamers and Dr. Thomas Böhm, focusing on Toll-like receptor signaling. She later re-joined Oncotest, holding leadership positions in in vivo contract research as well as R&D.